Boston goes full steam ahead with Guidant bid and formalises $25bn offer
This article was originally published in Clinica
Executive Summary
Boston Scientific formalised its bid for Guidant this week with a definitive offer to buy the cardiac rhythm management (CRM) specialist in a $25bn cash-and-stock transaction.